Luropean Journa of
`nca Pharmacoogy
`
`Froeso
`
`oh
`
`ov
`
`Ha
`
`ae is
`
`etor Flar bu
`
`ann
`von Ha fn berg
`
`Hefrr he
`
`Be ir
`
`borg Coponhag
`thaTo oi
`ra
`
`Ja
`
`Pra
`oyo Ease
`iu
`ai or
`er Base
`lal Heriord
`
`at
`
`ae
`
`KM
`
`01
`
`La do
`
`Oc
`
`urch
`
`IJs nki
`
`Base
`
`Ma
`Meyc
`orse
`ian
`an
`Nette Wrbu
`Aiisterda
`EOirhiut KaJ
`Ma Icy DubOn
`
`Dif
`
`rh
`
`werpoo
`3orr
`airono
`ewig Du
`
`ki
`
`Pr
`
`ía
`
`rn
`
`di bu oF
`
`escott
`Rarray SFoThe
`Uppsaa
`Pan
`es
`Poos Uppsala
`ossu
`4jrreoei
`var
`F-.W ybe
`Sjoqvvt
`
`udd go
`yr Thraen
`
`Ste
`Vette Zr
`
`Eta
`
`Va ko toc io
`ett Vi
`
`br
`
`ur
`
`Copy and
`Lang age Edito
`
`eoenhari
`yar
`eldt Ha de
`
`xrg
`
`lii
`
`ity
`
`ure34 1988
`
`anag ig Ed
`
`K4
`
`Do
`
`crr
`
`3or
`
`Ka
`
`Ba
`
`Ft de
`Bakke Bor ci
`
`ne
`
`or or
`
`Bi oF
`
`igo
`
`at
`3reck
`do
`auo Ge
`Baa
`
`rp
`
`opo
`Da
`
`Ba ii
`
`vrt
`
`iddi ge
`
`io
`
`rag
`
`Ge
`
`La
`
`Sti
`
`aart
`
`nger
`
`er ationa
`
`MYLAN - EXHIBIT 1022
`
`

`
`Copynght
`
`or
`
`ar
`
`ipi
`
`Ita
`
`do
`
`yt
`iuthor agree to aut
`
`Il
`riatle tranter of
`
`copyrIght
`
`ID the
`
`bod
`
`oF
`-oI ab
`we
`ubi shot
`
`is
`
`DC
`
`pubh
`otorr
`
`or
`
`p1
`
`tb
`
`to
`
`of
`
`pa
`
`of
`
`pubhhad
`
`list
`
`Ifs
`
`at uwr pt
`
`1w
`not
`
`erF
`let od elsewhere
`
`sty
`
`go
`
`io It
`
`it
`
`phI
`
`oF
`
`aI
`
`nIas
`
`rt
`
`\t
`
`iatr stiLl
`
`let
`
`JCUIS
`
`layb
`
`pIt
`
`ds
`
`tot
`
`pr
`15110sF
`
`Spun
`
`\ulap GnihI
`
`d1
`KG
`
`Itu ho
`
`dt
`
`toed
`
`lflI
`
`ill
`
`ler
`
`stabs
`
`

`
`Cli Pharmacol
`
`1985 34 js
`
`European Journa
`Cnca Pharmacogy
`S8
`
`cl
`
`Spn
`
`St
`
`es ir
`
`ii ai Drug
`
`opw ent
`
`\J
`
`ne
`
`rlaid
`
`the
`
`Ii
`
`lii
`
`-L
`
`nici
`
`sW cs Th
`at
`
`icr
`
`stud is
`pm
`do
`
`he
`
`ii
`
`ii
`
`ie
`
`ien
`
`of ci ut th
`he the Ipeutic
`ii
`
`ii
`
`ci
`
`lo
`
`tim durition of
`
`the cr cci
`
`iiipr
`
`ib
`
`ci
`
`ne
`dose
`
`it
`
`hi
`
`mr
`
`iii
`
`ru
`
`ci
`
`rar
`
`dci
`
`ie
`
`ii
`
`ii
`
`ii
`
`Cc
`
`rose lTnd
`
`mimi
`
`in
`
`ic
`
`kict
`
`in
`to croon
`
`rim
`
`cd
`dosag chedul
`
`ito
`
`cquirc
`
`se
`
`nc
`
`rr inda
`
`it
`
`tI at
`
`or
`
`fixcd
`
`Icing
`
`na
`
`udi
`
`is
`
`cc it
`
`Ition
`st dy sxws tie cpt
`
`ii
`
`ol
`
`dc
`
`oses
`
`ora
`icr
`
`st conta
`
`ii
`
`it
`
`it or
`
`fuid
`
`im
`
`to
`
`lou
`
`ci
`
`ci
`
`janc
`
`cis in
`
`ase
`
`ic
`
`ther
`
`ii niic
`
`rc
`
`cs 1rg
`
`flIt
`
`pn
`at
`
`mtcr
`
`aid
`
`ts
`
`vmn ii
`at
`exç
`
`Is
`
`equrci
`
`fort
`
`procc lure
`
`ge cr
`
`suge
`
`a1s
`
`de
`
`ibol
`
`lr
`
`mo
`
`de
`
`ho to
`
`Is
`
`IV
`
`ot
`nccd
`poor okra iii
`
`ir
`
`cx eed
`
`ci
`
`ji
`
`WI eli ci hea hy
`icc cd dcpc
`ds arc
`
`ax
`
`fleer
`
`im
`
`or pa cents xr
`ratio
`
`os
`idirg
`lcrai utic dosc
`
`ii
`
`dcv lopinen
`mnical
`gc pro osed rr cedric
`
`If
`
`isa or
`
`JJeallh
`
`Volunteers
`
`nvclvemcn
`
`The
`
`tud
`
`ituati
`
`tie th
`
`31
`
`ci mcal developmcnt of
`id di
`cc
`imases
`
`nais
`
`late
`
`id
`
`tr
`
`in
`
`ew drug is usually
`hase
`deso ed
`cat on
`macc
`m- die eval
`te Of
`Ph ts
`as
`or ear
`are
`ied at
`xl efica
`ie atended
`lucidr
`alien
`ing lini
`mat
`and to Iefnc the do gc aid dosagc
`chedu
`Control cci
`are perforif ed subse
`cw drug
`idard
`tIre St
`il ar pcr
`safct
`tim
`
`ci Ily to compare the
`ed
`hase III
`lions In
`large se.r
`mcd to confirm tie. cmcicy
`in the targct population
`the dosag mci dseg sc
`Dc in
`ulc
`in of
`Ikvot stor
`ancw
`rg ci
`dese
`ire
`so allcd dose
`obje
`
`tr
`
`ii
`
`is
`
`ye of
`
`1c th
`ted
`iffic ally ye ii
`pccif cally mentioncd
`down
`tIre 1915 Tokyo
`Dcc cration of Filelsrn
`or
`drugs to ieatthy vo untecr
`saon for it
`
`un rics
`in the Guide
`md
`
`kcis
`
`im
`
`it
`
`the
`
`Ira cc
`dm strat
`ftc
`or bcs
`
`laid
`
`964
`
`gal
`
`rov
`
`rid
`adi art ages
`
`Itly Vi
`
`rs las thc
`
`iflo mw
`
`They arc
`show or
`as
`dy
`no variation due to disease
`
`itili
`
`no dffcrcnt
`torect
`
`ea
`sy to se cci
`
`st gc
`
`eu
`
`disease
`
`tor ige ac
`
`ct
`
`

`
`conditions climate food
`
`tcstcd undcr
`identical
`atoraryvau
`no taking con
`
`cd cltir
`olin vriting
`re to
`sily
`condition in which the test can be rcpcated
`
`Lii
`
`in
`
`crs
`
`pr
`
`ctalili
`
`tl
`
`ii Cf
`
`Iose ranging studics can be only performed um
`test mod
`hut
`cRib
`orn
`volur
`hcrapcutic 4fet
`vith hiti
`induced
`achyc
`id
`cffect
`
`prese it
`rg in ci
`by
`ock
`ta
`tiosofdgcricr
`mdi
`tamine flare tnt for antihis amanes
`et
`Thc disadvantagcs of trcating hcalthy volunteers
`cr cf
`pt ni 11
`icy carrot
`tha
`udes that
`of gharira dyrar
`th
`
`or
`
`ct
`
`indo
`pudhis-
`
`ir
`
`ft
`
`id
`
`it
`do not sho
`cr
`
`ti
`
`is
`
`lo icc
`
`or
`
`sv
`
`tachy rrdai
`sted
`
`rg nr
`at or
`In this nay the new suhst
`ince can be
`thcr and to wh extcr
`gard
`Ft gokl
`IIU
`rid
`
`it
`
`IC
`aalo
`
`ii
`
`Ii
`
`ft
`
`ib
`
`irt
`
`en
`
`aim RI
`
`itt
`
`is
`
`IF
`
`mding St
`
`hc mon in
`the clii
`
`ti
`
`invcsti ator
`
`tha
`
`tho
`
`hi
`
`in
`
`fined but also its giavity and stac
`ar
`drug the iir
`novi
`ccnpa
`th
`cxp
`dma to sckct
`id stage paticnts ra
`his na result
`in an carly stage of tie diseasc
`the recommendation
`dosige for the
`too high
`of
`study population in Phases II and Ill
`Iheic
`trials
`the involve 11 nt of patients with different but
`fort
`nd dcfincd
`us cn ial
`th
`sages ci
`in
`ant
`ntcrgre ilion of
`tudie
`th
`deg
`
`se 11
`
`idi
`
`su ts
`thcdi
`
`in
`
`ike rot
`
`ic in
`
`se
`
`tatc
`
`is
`
`Stu
`
`tsign
`
`Whcthcr
`Tv thai
`
`arallcl
`
`se
`
`dos
`
`ti
`
`ti
`
`ii
`
`cr
`
`sa
`
`rapati
`nc
`roup dc
`cr
`should be chosen depends on the ii sture of
`essc an on thc
`conditi
`tic paticiits Only
`fl
`of
`tcy
`Lcd
`nd
`iij
`
`amc
`vhe
`
`the dis
`
`gv
`
`dlii
`
`ci
`
`If
`
`xpe
`
`atm
`
`ri
`
`it
`
`ci
`
`III
`
`IL
`
`11 fl
`
`sleep es ok by classic ml
`UL II
`LW
`
`cL55 LUI
`
`intadepress ants
`LLLCU Ui 5Cc
`
`ti
`
`ar
`
`an
`
`to
`
`tFi
`disc ase process can be chosen
`aim open design rim my
`SW 111 ILi
`SUL7JL ILl VI SYUI1LUII1S UI SyII
`Iihthcclç
`
`VV
`
`ii
`
`Ii
`
`ii
`
`iii
`
`th
`ft
`
`dr
`
`identif at inon tests
`rncthod
`
`thusc Lcst
`
`Id
`
`of
`
`ii
`
`icu
`
`it
`
`Ii
`
`II
`
`coot
`
`ch
`ihove only
`As miientioned
`should tic uscd whosc prcdmcta
`
`-sit
`
`Definition of the Optimal Dosage
`
`stu
`
`sh
`
`ci
`
`nir
`
`ft
`
`ci
`
`tv
`
`ft
`thixir
`tIm optimal dc sc
`
`ingc
`
`win
`
`cc iv
`
`line
`
`or
`
`Ic
`
`in
`
`ct
`
`Since ills
`
`th re
`th
`
`tic
`
`stu
`
`cs
`
`cscc
`
`ta
`
`ish
`
`idda
`
`lit
`
`it
`
`The pert mm nice of dosc rinprig
`
`udies an pan ohs
`
`is
`
`ii
`
`ry
`
`iii
`
`Si
`
`ic
`
`itt
`
`unosuç
`
`it
`
`ci
`
`cs
`
`cc
`
`for
`
`ours Si
`valid test mode an healthy volunteers
`tom scnic dcmcntia parkmnsonism ctc
`
`tic
`
`yt
`
`dr
`
`hal at
`
`hr mdi
`taicly and quantatitrvelv
`
`sh
`Id hi
`qu ala
`far
`Not only the dIsease for
`
`ft
`ni ni
`rr
`the goal with most deve pmentai druUs
`to paoducc
`activity amid
`grcatcr
`thcrapcutic
`larg
`rt.snondcrs than cornoctitor diurs
`er nronnrtion of
`of choo irti
`ima Ic ci
`bilt
`
`Fcr
`
`co iarcndat
`mc ita
`cd
`thc
`lo
`gh
`to
`shine th selection of severely disrbed or end
`
`Ru
`
`to
`
`

`
`ict5Dn
`
`nd5nStud
`
`rule th it
`
`the high
`of side
`fe
`
`ited
`
`re in
`
`cc
`
`md
`
`it
`
`ne
`
`el
`
`of
`
`the
`
`pr
`or tde ib
`
`Jr
`
`tn
`
`an
`
`mud the gene
`keep
`the higher the inciden
`ge and toler thu
`rs ly eorr
`he utm ut import
`define the 1osition
`tim ii do
`twe
`ran
`tf
`ru
`al
`effective doses Within the optimal
`ixu
`ranue true uesired therapeutic efteet should be
`iLl goo
`or
`hi ity
`this mean5 LI
`fleaey
`idvantaoe
`er coup ti
`deli it
`ior
`ri
`osided tat
`up rionty will Fe
`possible double hhnd
`oritrolied if
`iss II and III
`leraluhtx
`
`tidies
`
`ase
`
`ue hug
`
`to
`
`cc
`Ies
`
`cit
`
`se
`
`ii
`
`db
`
`idara
`
`tu
`
`ci
`
`iv ak
`
`ii
`
`bi
`
`ch
`
`10
`doshiidui stud
`
`dot
`
`rah
`
`if
`
`further des elopnueut of
`tion becomes
`dd
`
`ques ion able
`trod
`
`the drug for the selected in
`thc ha lest VC
`ie tlvcoe
`Fuich
`
`II
`
`dos
`
`et
`
`a1
`
`rib
`WF
`ieeho should he included to
`
`siuble
`vet
`tfl 4L
`etc it
`indication
`
`05
`
`Ci
`
`ru
`
`opt nil
`
`siy
`ulepao
`
`Fhtc
`sd
`
`Ic
`
`nut
`
`Ic
`
`lose
`
`5ur
`
`sf
`
`which
`
`4flV4
`
`SVSfl
`
`Llfl
`
`nust
`flJ LVJ
`1fltJVSflLV JX
`in the two curves ii Jib it
`is esadent
`
`and opulatuoui
`
`ponders
`
`iii
`
`Jolt
`nun
`eliectase
`
`In tlu ma 111
`dose
`and
`the
`
`ruE It
`
`Lw lb
`
`ii xi
`
`ii
`
`ly
`th
`
`rniraanu ii
`
`elf ectus
`
`utn dost
`
`If
`
`ti
`
`se
`
`euuve Lff
`
`lie
`
`ii
`
`II
`
`the
`
`ii can effectaic
`mx
`
`/\
`
`Ii
`
`II
`
`wI
`
`5c
`
`in
`
`to
`nab ty eurv
`tam ii er5
`is broad more th in one dos
`tab or it may
`lund
`
`iangc
`selected
`
`ill
`
`ii
`
`ic
`
`pi
`
`tIe
`
`ii
`
`xc
`se
`icscv hut only worsen tolera
`further ancra 5c
`Below the minim il effeetase do
`lies the no
`tar IL hat
`is the nane
`dt
`laceb
`ciii
`
`ma
`
`lit
`
`01
`
`ir
`
`dv
`
`iu
`
`iii
`
`III
`
`ts
`and apicity the numbers of dose
`in comparitis
`as possible md should not
`tuaals should be is situ ill
`poss hi
`usually cx eed th cc
`ocx
`id
`di
`acs it
`
`Im
`
`eic
`
`LI
`
`cL
`
`is
`
`or
`
`Ad
`
`an
`
`is
`Laid tIe
`
`Ic ul
`
`or
`point
`or sonue indications the placebo response
`in
`
`he
`turt
`low the 100
`
`ly st
`at cue
`
`ag
`
`LI
`
`11
`
`iw ire
`
`ma
`
`od ac
`
`effect
`
`ninf
`
`itt
`
`cc
`use
`mccl
`
`dci
`
`is
`
`ud
`
`fir dii
`
`tr
`
`hut or
`
`ea
`
`tpI In
`
`ant
`
`as
`
`it es
`marlv
`
`For sonic compounds an igesies
`in endoca1noIoy
`etc
`
`diuretics dop
`single dost or
`
`arniaacrgies
`srg
`
`çç
`
`at
`
`pe
`
`ring
`tlcr drugs
`cc
`
`sa
`
`veil
`
`it
`
`il diys or
`ho it
`
`edule
`
`ls
`
`

`
`ef
`
`tion
`
`Do ag Schedu
`
`The du anon of act
`iould be dctern
`ied during
`ll
`ahoy de mi ion of
`do
`finding st dl
`the dosage schedule Unfortunately for some sub-
`stances nootropics immunoactive
`drugs etc the
`duration of action is rim cult
`to detejininc during
`arly clinical haL
`anc
`cUrl
`
`th
`na odyna
`
`rr as ira
`cTsil
`par meter Othr
`ken
`isider
`
`er
`wli Ii
`
`st
`
`na
`
`iust
`
`ugge
`
`dule ifi
`
`xa
`
`IL
`
`ntative
`
`sigc
`
`Le
`
`half lives in plasma and urine in man and various
`test .e ies
`
`at
`Ic
`
`in
`
`de
`
`asc
`
`ts
`
`bi
`
`-gns
`
`tc
`
`ccum
`
`to
`
`ci
`
`flock
`Ird
`wh
`Irtl
`tlgI
`ififel
`re
`prolonged dur thou of action
`is ikeIy to leid to
`ia odxnamre eata ii siso in amm Is
`phar
`
`let
`
`RSchnidt
`
`Do
`
`idi
`
`tStudi
`
`drawn Turing the day
`ii suit ce to yros de the in
`am
`co eat an fl
`rofile
`vidual
`flo
`the sam
`ould
`cssr er
`crability
`ts to rcvel th correlation betwe
`tim pcii
`blood
`the zero basal
`lei ci and actisity Usually at
`and the
`value
`the
`iximal concentration
`The results of mc inn
`nouyn level are detenninea
`must ye used to help to
`pharmacoki
`ietic stu
`de ign Ii
`udi
`
`rr
`
`least
`
`par of
`
`the dose-findin
`
`to hi ns
`
`The dose-finding
`dr
`xc
`
`te
`
`if
`
`co
`
`pa
`
`stud1
`
`occupies
`
`pr
`
`iii
`
`ke1 position in
`rL dcsgnrd
`and
`
`If
`
`IT
`
`lar
`
`Ic
`
`Ir ii
`
`ses Il
`P1
`nit
`
`HI
`
`he
`nil
`ts equred ltrnuttwdcne call
`fpati
`the end of
`lb ise
`duirny the clinical studies
`at
`llasc II
`tIe hegmnrir
`
`or at
`
`of
`
`It
`
`nust
`
`inelud
`
`icr
`
`ar
`
`oss
`
`dy
`
`it
`
`Ti
`
`ure
`
`it
`
`re
`
`ct
`dur eg
`ot
`
`veil
`
`si
`
`an
`
`If
`ed
`
`iic
`Itt
`
`tl
`
`idI
`
`ic
`
`ci
`
`Ii
`
`sponsc cum
`
`ie oft ic
`
`es
`
`irieans to dciii
`
`ftc
`
`eiet
`
`as
`
`lurit
`
`ur
`
`cf action
`sub ta cc
`
`eo
`
`tic be
`
`Blood oncentratlo Rs
`
`xe
`
`merts
`
`he
`and iliow
`
`in hcaitly
`cc
`nal
`
`rr
`
`ye
`
`rr
`
`volunteers
`
`crc
`
`or
`ar
`
`Pharmacokinetic
`studies
`ic ts and p1
`era cut
`durinh
`harinacok
`tudi
`et
`tnc aCm te
`Uo
`of it
`In
`lisma concentration measurement
`ters
`in healtly
`volu teers and patients correlate the plasma con
`atc with the quah
`and quartity rf desire
`cr
`ci fees
`er
`
`ti
`
`imonto
`
`pins
`
`ng
`
`th stu Is popi atmoir
`rpac
`
`cic ci
`
`ry
`le
`
`ye
`
`pate
`
`ot
`
`el
`
`dose
`
`coc irge
`in
`rix
`inc
`cfl
`is the no effect dose or placebo
`
`is well
`
`range
`duration of action and dosage schedule
`resi ois
`concntrt or
`bloed
`rni
`
`rye
`
`10
`
`ao
`
`fi acy
`iar
`
`ivo
`fl
`
`-t
`
`it
`
`uc so
`
`to
`
`iced
`aticrlts
`three doses for corn ama
`the ii
`tive trials ml avoid whenever possible individual
`dose titration
`ccnfirr
`
`olcr bili
`
`nfl
`
`rena
`
`ferzres
`
`gplasiaconcnt ato
`con
`during lose-f
`ig studi
`per
`it at i1
`range to be defined within wi ich the desired effects
`ibis will show whether there is
`or side effects occur
`tor Ic ween
`lIe tive ess ind blood lexel
`ieth
`
`err
`and
`
`il
`
`cv
`
`diet- respons
`ring of blood
`properly designed plan of the
`sampling and effec measurerients will provide
`mc
`liable answ
`abo
`concentration-re
`bloc
`the
`few about
`blood simples
`sponse curie
`
`ii
`
`14
`
`ith
`
`tin
`
`of
`
`it
`
`Iralth Ed catior and \VeIfr
`ii
`of
`Ffll u4
`inn 107
`ug Adni ci
`vi
`No77 3040 Cencial Considerations
`ror the Clinical Lvaiua
`040
`Washing
`SH 177
`DL
`In Johnson UN and Johnson
`usc
`Blackwell Oxford London
`1982 JO crnmcnt
`Ic upic
`Drug Information
`10 17
`
`ill
`
`ii aboratoryto rincr
`cds Clinical
`rrials
`
`dinburgi
`siesspoirt of
`
`ci mc
`
`trials
`
`

`
`It Dose huding Studio
`
`et
`
`is Select on of
`
`tiga
`
`Do gkr Hi 1973 arty humar
`In 1inie1
`acolo
`cii evalea ion
`ul
`oti RporL rn
`Nov 72
`Sriposium Heidelberg
`VH ed Cope iti ne pp 29 36
`
`ild
`
`die ii
`
`oiL on
`
`51
`
`Ja an
`Dion
`
`rpaiilanae
`ru in
`
`41
`
`Mathe
`
`uie 00
`
`160
`1386 rop sals
`iu
`
`iur
`
`Ii
`
`Helsin
`
`or ethical
`Pap Chu
`
`12
`
`tniidt
`
`idust
`
`chinidt
`
`19
`198
`IIirnaehe Pharniakoiogie
`Mhekeiten
`id
`cir
`ed Therapiev
`rsueh an
`iischott Win
`19
`Nieht
`
`inv
`
`Ic hoder
`
`in
`
`LI
`
`ii
`
`cher
`
`in dr Pharma
`Ii 1i
`no
`oath ii
`
`hien
`
`ci
`
`lit
`
`ak
`
`49
`
`Ach 131983 11 eel oft
`pieg
`leq oly
`hop
`IN
`Wiley
`10 Grdwey
`bos
`
`Cr
`
`Li
`
`hi he to
`1083
`\s
`
`gude to the phuinaeohgy
`
`of place
`
`19
`
`ph
`gy
`
`ii
`
`ia Ut Cd
`
`fl RUL
`
`11 Sin
`mum In
`up inc
`
`Me
`Lin
`19
`IL rii
`tour une ireilleure appre
`en
`
`ile
`
`ii
`
`ii pr
`
`nion
`
`Ia po ologie
`
`oS
`
`Received
`
`epler
`
`\Isy IS 1987
`Iun
`
`RS Jr idt
`SN 0/ Ltd
`
`401
`
`as
`
`if